Rana, Sareena

Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA

Coelho, M. A., de Carné Trécesson, S., Rana, S., Zecchin, D., Moore, C., Molina-Arcas, M., East, P., Spencer-Dene, B., Nye, E., Barnouin, K., et al. (2017) · Immunity

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 653

Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer

Molina-Arcas, M., Moore, C., Rana, S., van Maldegem, F., Mugarza, E., Romero-Clavijo, P., Herbert, E., Horswell, S., Li, L.-S., Janes, M. R., et al. (2019) · Science Translational Medicine

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 203

Abstract 4029: Combination of KRASG12C(ON) and SHP2 inhibitors overcomes adaptive resistance and enhances anti-tumor immunity

Anastasiou, P., Mugarza, E., Boumelha, J., Rana, S., Moore, C., Molina-Arcas, M., & Downward, J. (2022) · Cancer Research

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 3